S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
OTCMKTS:BNKL

Bionik Laboratories - BNKL Stock Forecast, Price & News

$0.27
0.00 (0.00%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.27
$0.27
50-Day Range
$0.25
$1.00
52-Week Range
$0.25
$2.42
Volume
N/A
Average Volume
165 shs
Market Capitalization
$1.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BNKL stock logo

About Bionik Laboratories (OTCMKTS:BNKL) Stock

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.

Receive BNKL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionik Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BNKL Stock News Headlines

BIONIK Laboratories Corp. Appoints Rich Russo, Jr. as CFO
See More Headlines
Receive BNKL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionik Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BNKL Company Calendar

Last Earnings
6/09/2022
Today
8/13/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BNKL
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-10,410,000.00
Net Margins
-1,342.13%
Pretax Margin
-1,342.13%

Debt

Sales & Book Value

Annual Sales
$1.27 million
Book Value
$0.24 per share

Miscellaneous

Free Float
4,035,000
Market Cap
$1.83 million
Optionable
Not Optionable
Beta
-0.83

Key Executives

  • Mr. Richard Paul Russo Jr. (Age 41)
    CPA, CFO & Interim CEO
    Comp: $298.6k
  • Mr. Michal Prywata (Age 31)
    Co-Founder & Director
    Comp: $585.87k













BNKL Stock - Frequently Asked Questions

How have BNKL shares performed in 2022?

Bionik Laboratories' stock was trading at $0.80 at the start of the year. Since then, BNKL stock has decreased by 66.2% and is now trading at $0.2701.
View the best growth stocks for 2022 here
.

How were Bionik Laboratories' earnings last quarter?

Bionik Laboratories Corp. (OTCMKTS:BNKL) announced its earnings results on Thursday, June, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter. The company earned $0.19 million during the quarter. Bionik Laboratories had a negative net margin of 1,342.13% and a negative trailing twelve-month return on equity of 975.04%.

What other stocks do shareholders of Bionik Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionik Laboratories investors own include Co-Diagnostics (CODX), iBio (IBIO), PerkinElmer (PKI), PharmaCyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Ascent Solar Technologies (ASTI), BioRestorative Therapies (BRTX) and Digital Ally (DGLY).

What is Bionik Laboratories' stock symbol?

Bionik Laboratories trades on the OTCMKTS under the ticker symbol "BNKL."

How do I buy shares of Bionik Laboratories?

Shares of BNKL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionik Laboratories' stock price today?

One share of BNKL stock can currently be purchased for approximately $0.27.

How much money does Bionik Laboratories make?

Bionik Laboratories (OTCMKTS:BNKL) has a market capitalization of $1.83 million and generates $1.27 million in revenue each year. The company earns $-10,410,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How can I contact Bionik Laboratories?

Bionik Laboratories' mailing address is 483 Bay Street N105, Toronto A6, M5G2C9. The official website for the company is www.bioniklabs.com. The company can be reached via phone at 617-926-4800 or via email at lm@bioniklabs.com.

This page (OTCMKTS:BNKL) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.